Login / Signup

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Annika FendlerLewis AuScott T C ShepherdFiona ByrneMaddalena CerroneLaura Amanda BoosKarolina RzeniewiczWilliam GordonBenjamin ShumCamille L GerardBarry WardWenyi XieAndreas M SchmittNalinie Joharatnam-HoganGeorgina H CornishMartin A PuleLeila MekkaouiKevin W NgEleanor CarlyleKim EdmondsLyra Del RosarioSarah SarkerKarla LingardMary MangwendeLucy HoltHamid AhmodRichard StoneCamila Araujo De Carvalho GomesHelen R FlynnAna Agua-DocePhilip HobsonSimon CaidanMichael HowellMary Y WuRobert GoldstoneMargaret CrawfordLaura CubittHarshil PatelMike GavrielidesEmma NyeAmbrosius P SnijdersJames I MacRaeJérôme NicodFirza GronthoudRobyn L SheaChristina MessiouDavid CunninghamIan ChauNaureen StarlingNicholas TurnerLiam WelshNicholas van AsRobin L JonesJoanne DroneySusana BanerjeeKate C TathamShaman JhanjiMary O'BrienOlivia CurtisKevin J HarringtonShreerang BhideJessica BazinAnna RobinsonClemency StephensonTim SlatteryYasir KhanZayd TippuIsla LeslieSpyridon GennatasAlicia OkinesAlison ReidKate YoungAndrew J S FurnessLisa M PickeringSonia GandhiSteven J GamblinCharles Swantonnull nullEmma NicholsonSacheen KumarNadia YousafKatalin Andrea WilkinsonAnthony SwerdlowRuth HarveyGeorge KassiotisJames LarkinRobert J WilkinsonSamra Turajlicnull null
Published in: Nature cancer (2021)
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4 + responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.
Keyphrases